{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:54:47Z","timestamp":1769838887598,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T00:00:00Z","timestamp":1273104000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s11154-010-9137-1","type":"journal-article","created":{"date-parts":[[2010,5,5]],"date-time":"2010-05-05T09:16:18Z","timestamp":1273050978000},"page":"253-259","source":"Crossref","is-referenced-by-count":22,"title":["SERMs and SERMs with estrogen for postmenopausal osteoporosis"],"prefix":"10.1007","volume":"11","author":[{"given":"Michael A.","family":"Bolognese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,6]]},"reference":[{"key":"9137_CR1","first-page":"52","volume":"45","author":"H Taylor","year":"2010","unstructured":"Taylor H. Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis. Formulary. 2010;45:52\u20139.","journal-title":"Formulary."},{"key":"9137_CR2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","volume":"12","author":"AC Looker","year":"1997","unstructured":"Looker AC, Orwell ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761\u20138.","journal-title":"J Bone Miner Res."},{"key":"9137_CR3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. Frax and its application in clinical practice. Bone. 2009;44:734\u201343.","journal-title":"Bone."},{"key":"9137_CR4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Int Med. 2004;164:1108\u201312.","journal-title":"Arch Int Med."},{"key":"9137_CR5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteston A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res. 2007;22:465\u201375.","journal-title":"J Bone Miner Res."},{"key":"9137_CR6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(05)66400-8","volume":"365","author":"U Veronesi","year":"2005","unstructured":"Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet. 2005;365:1451\u201367.","journal-title":"Lancet."},{"key":"9137_CR7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371\u201388.","journal-title":"J Natl Cancer Inst."},{"key":"9137_CR8","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.151.9.1842","volume":"151","author":"RR Love","year":"1991","unstructured":"Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842\u20137.","journal-title":"Arch Intern Med."},{"key":"9137_CR9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(05)72466-1","volume":"355","author":"JJ Dignam","year":"2000","unstructured":"Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet. 2000;355:848\u20139.","journal-title":"Lancet."},{"key":"9137_CR10","unstructured":"Evista (Raloxifene HCL) (Package insert). Indianapolis, IN: Eli Lilly and Company, 2007."},{"key":"9137_CR11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.5650110615","volume":"11","author":"MW Draper","year":"1996","unstructured":"Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY 139481) HCL; impact on bone turnover and serum lipid profile in healthy Postmenopausal women. J Bone Miner Res. 1996;11:835\u201342.","journal-title":"J Bone Miner Res."},{"key":"9137_CR12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641\u20137.","journal-title":"N Engl J Med."},{"key":"9137_CR13","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","volume":"160","author":"CC Johnston Jr","year":"2000","unstructured":"Johnston Jr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials. Arch Int Med. 2000;160:3444\u201350.","journal-title":"Arch Int Med."},{"key":"9137_CR14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.GME.0000058772.59606.2A","volume":"10","author":"EE Jolly","year":"2003","unstructured":"Jolly EE, Bjarnason NH, Nevan P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5\u00a0years. Menopause. 2003;10:337\u201344.","journal-title":"Menopause."},{"key":"9137_CR15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archinte.164.8.871","volume":"164","author":"IR Reid","year":"2004","unstructured":"Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med. 2004;164:871\u20139.","journal-title":"Arch Intern Med."},{"key":"9137_CR16","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"S Cummings","year":"1999","unstructured":"Cummings S, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 1999;281:2189\u201397.","journal-title":"JAMA."},{"key":"9137_CR17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene; results from a 3-year randomized clinical trial. JAMA. 1999;282:637\u201345.","journal-title":"JAMA."},{"key":"9137_CR18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"PD Delmas","year":"1999","unstructured":"Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis; four year results from a randomized clinical trial. JAMA. 1999;282:637\u201345.","journal-title":"JAMA."},{"key":"9137_CR19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751\u201361.","journal-title":"J Natl Cancer Inst."},{"key":"9137_CR20","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","volume":"20","author":"ES Siris","year":"2005","unstructured":"Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8\u00a0years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2005;20:1514\u201324.","journal-title":"J Bone Miner Res."},{"key":"9137_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.maturitas.2005.03.010","volume":"52","author":"P Neven","year":"2005","unstructured":"Neven P, Quail D, Martin F, et al. Comparing raloxifene with continuous combined estrogen-progesterone therapy in postmenopausal women: review of Euralox 1. Maturitas. 2005;52:87\u2013101.","journal-title":"Maturitas."},{"key":"9137_CR22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125\u201337.","journal-title":"N Engl J Med."},{"key":"9137_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/OGX.0b013e31816400d7","volume":"63","author":"W Shelly","year":"2008","unstructured":"Shelly W, Draper M, Krishman V, et al. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008;63:163\u201380.","journal-title":"Obstet Gynecol Surv."},{"key":"9137_CR24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1359\/JBMR.040508","volume":"19","author":"E Siris","year":"2004","unstructured":"Siris E, Harris S, Eastell R, et al. Effects of raloxifene on the risk of non-vertebral fractures after 8\u00a0years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2004;19:896.","journal-title":"J Bone Miner Res."},{"key":"9137_CR25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"J Cauley","year":"2001","unstructured":"Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene; 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125\u201334.","journal-title":"Breast Cancer Res Treat."},{"key":"9137_CR26","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA. 2006;295:2727\u201341.","journal-title":"JAMA."},{"key":"9137_CR27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","volume":"21","author":"S Martino","year":"2005","unstructured":"Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441\u201352.","journal-title":"Curr Med Res Opin."},{"key":"9137_CR28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0029-7844(98)00476-1","volume":"93","author":"GC Davies","year":"1999","unstructured":"Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93:558\u201365.","journal-title":"Obstet Gynecol."},{"key":"9137_CR29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/01.GME.0000151653.02620.89","volume":"12","author":"CS Duvernoy","year":"2005","unstructured":"Duvernoy CS, Kulkarni PM, Dowsett SA, et al. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause. 2005;12:444\u201352.","journal-title":"Menopause."},{"key":"9137_CR30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","volume":"104","author":"D Grady","year":"2004","unstructured":"Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104:837\u201344.","journal-title":"Obstet Gynecol."},{"key":"9137_CR31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00042192-199906030-00003","volume":"6","author":"GC Davies","year":"1999","unstructured":"Davies GC, Huster WJ, Shen W, et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause. 1999;6:188\u201395.","journal-title":"Menopause."},{"key":"9137_CR32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1006\/gyno.2001.6578","volume":"85","author":"P Neven","year":"2002","unstructured":"Neven P, Goldstein SR, Ciaccia AV, et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol. 2002;85:388\u201390.","journal-title":"Gynecol Oncol."},{"key":"9137_CR33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0029-7844(01)01390-4","volume":"98","author":"SR Goldstein","year":"2001","unstructured":"Goldstein SR, Neven P, Zhou L, et al. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol. 2001;98:91\u20136.","journal-title":"Obstet Gynecol."},{"key":"9137_CR34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00042192-200512020-00010","volume":"12","author":"SR Goldstein","year":"2005","unstructured":"Goldstein SR, Johnson S, Watts NB, et al. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause. 2005;12:160\u20134.","journal-title":"Menopause."},{"key":"9137_CR35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.AOG.0000109429.67671.d1","volume":"103","author":"LE Waetjen","year":"2004","unstructured":"Waetjen LE, Brown JS, Modelska K, et al. Effect of raloxifene on urinary incontinence; a randomized controlled trial. Obstet Gynecol. 2004;103:261\u20136.","journal-title":"Obstet Gynecol."},{"key":"9137_CR36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.amjcard.2005.09.083","volume":"97","author":"K Ensrud","year":"2006","unstructured":"Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol. 2006;97:520\u20137.","journal-title":"Am J Cardiol."},{"key":"9137_CR37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM200104193441604","volume":"344","author":"K Yaffe","year":"2001","unstructured":"Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Eng J Med. 2001;344:1207\u201313.","journal-title":"N Eng J Med."},{"key":"9137_CR38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1176\/appi.ajp.162.4.683","volume":"162","author":"K Yaffe","year":"2005","unstructured":"Yaffe K, Kreuger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005;162:683\u201390.","journal-title":"Am J Psychiatry."},{"key":"9137_CR39","first-page":"S230","volume":"44","author":"M Bolognese","year":"2009","unstructured":"Bolognese M, Krege J, Utian W, et al. OC45; Arzoxifene in postmenopausal women with normal or low bone mass. Bone (supplement). 2009;44:S230.","journal-title":"Bone (supplement)."},{"key":"9137_CR40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/00016340500345691","volume":"85","author":"P Ravn","year":"2006","unstructured":"Ravn P, Nielsen TF, Christiansen C. What can be learned from the levormeloxifene experience? Acta Obstet Gynecol Scand. 2006;85:135\u201342.","journal-title":"Acta Obstet Gynecol Scand."},{"key":"9137_CR41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003495-200666020-00005","volume":"66","author":"TE Vogelvang","year":"2006","unstructured":"Vogelvang TE, van der Mooren MJ, et al. Emerging selective estrogen receptor modulators; special focus on effects on coronary heart disease in postmenopausal women. Drugs. 2006;66:191\u2013221.","journal-title":"Drugs."},{"key":"9137_CR42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015229630260","volume":"73","author":"A Budzar","year":"2002","unstructured":"Budzar A, Hayes D, El-Khoudary A, et al. Phase II randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER\/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002;73:161\u201375.","journal-title":"Breast Cancer Res Treat."},{"key":"9137_CR43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0268-0033(01)00110-3","volume":"17","author":"E Rietbergen van","year":"2002","unstructured":"van Rietbergen E, Majumdar S, Newitt D, et al. High-resolution MRI and Micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials; application to calcaneal bone in postmenopausal women after one year of idoxifene treatment. Clin Biomech (Bristol,Avon). 2002;17:81\u20138.","journal-title":"Clin Biomech (Bristol,Avon)."},{"key":"9137_CR44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7863\/jum.1999.18.7.503","volume":"18","author":"AC Fleischer","year":"1999","unstructured":"Fleischer AC, Wheeler JE, Yeh IT, et al. Effects of clomoiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. J Ultrasound Med. 1999;18:503\u201312.","journal-title":"J Ultrasound Med."},{"key":"9137_CR45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/156802606776173483","volume":"6","author":"EA Ariazi","year":"2006","unstructured":"Ariazi EA, Ariazi JL, Cordera F, et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6:181\u2013202.","journal-title":"Curr Top Med Chem."},{"key":"9137_CR46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/13697130500117946","volume":"8","author":"P Alertazzi","year":"2005","unstructured":"Alertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators; a systemic review. Climacteric. 2005;8:214\u201320.","journal-title":"Climacteric."},{"key":"9137_CR47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0091270005283280","volume":"46","author":"M Gardner","year":"2006","unstructured":"Gardner M, Taylor A, Wei G, et al. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol. 2006;46:52\u20138.","journal-title":"J Clin Pharmacol."},{"key":"9137_CR48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","volume":"13","author":"MR McClung","year":"2006","unstructured":"McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13:377\u201386.","journal-title":"Menopause."},{"key":"9137_CR49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"S Cummings","year":"2010","unstructured":"Cummings S, Ensrud K, Delmas P, et al. Lasofoxifene in postmenopausal Women with osteoporosis. N Engl J Med. 2010;362:686\u201396.","journal-title":"N Engl J Med."},{"key":"9137_CR50","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","volume":"146","author":"BS Komm","year":"2005","unstructured":"Komm BS, Kharode YP, Bodine PV, et al. Bazodoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146:3999\u20134008.","journal-title":"Endocrinology."},{"key":"9137_CR51","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","volume":"105","author":"S Ronkin","year":"2005","unstructured":"Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazodoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol. 2005;105:1397\u2013404.","journal-title":"Obstet Gynecol."},{"key":"9137_CR52","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","volume":"23","author":"PD Miller","year":"2008","unstructured":"Miller PD, Chines AA, Christiansen C, et al. Effects of bazodeoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:525\u201335.","journal-title":"J Bone Miner Res."},{"key":"9137_CR53","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/S0002-9378(97)70091-7","volume":"177","author":"SM Boss","year":"1997","unstructured":"Boss SM, Huster WJ, Neild JA, et al. effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458\u201364.","journal-title":"Am J Obstet Gynecol."},{"key":"9137_CR54","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/1933719108325759","volume":"15","author":"B Komm","year":"2008","unstructured":"Komm B. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008;15:984\u201392.","journal-title":"Reprod Sci."},{"key":"9137_CR55","doi-asserted-by":"crossref","unstructured":"Pickar J, I-Tein Y, Bachman G, et al. Endometrial effects of a tissue selective estrogen complex containing bazodoxifene\/conjugated estrogens as a menopausal therapy. Fertl Steril 2009;92:1018\u20131024.","DOI":"10.1016\/j.fertnstert.2009.05.094"},{"key":"9137_CR56","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1210\/en.2008-0817","volume":"149","author":"Y Kharode","year":"2008","unstructured":"Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen modulator, bazodoxifene, with conjugated estrogens as a new paradigmfor the treatment of postmenopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149:6084\u201391.","journal-title":"Endocrinology."},{"key":"9137_CR57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","volume":"92","author":"R Lobo","year":"2009","unstructured":"Lobo R, Pinkerton J, Gass M, et al. Evaluation of bazodoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025\u201334.","journal-title":"Fertil Steril."},{"key":"9137_CR58","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","volume":"92","author":"D Archer","year":"2009","unstructured":"Archer D, Lewis V, Carr B, et al. Bazodoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women. Fertl Steril. 2009;92:1039\u201344.","journal-title":"Fertl Steril."},{"key":"9137_CR59","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","volume":"92","author":"R Lindsay","year":"2009","unstructured":"Lindsay R, Gallagher J, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazodoxifene\/conjugated estrogens for osteoporosis preventionin at-risk postmenopausal women. Fertl Steril. 2009;92:1045\u201351.","journal-title":"Fertl Steril."}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-010-9137-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11154-010-9137-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-010-9137-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T04:31:02Z","timestamp":1635309062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-010-9137-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,6]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9137"],"URL":"https:\/\/doi.org\/10.1007\/s11154-010-9137-1","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,6]]}}}